Autoinjectors Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global autoinjectors market growth is projected to expand to a value of USD 3.02 billion in 2030 from USD 1.40 billion in 2024, with a significant CAGR of 13.6%. The autoinjector finished formulations market is projected to surge to a value of USD 134.27 billion in 2030 from USD 67.30 billion in 2024, growing at a CAGR of 12.2%. Technology advancements in autoinjector devices, such as improved design, the addition of connectivity features for data tracking, Bluetooth connectivity, and dosage reminders, are some of the factors that increase the adoption of autoinjectors and drive market growth. The prevalence of severe allergies also leads to a significant demand for products such as EpiPen (epinephrine autoinjectors), which are essential for emergency treatment in developed and emerging economies. Additionally, the increasing adoption of biologics and the growing prevalence of chronic diseases further boost the demand for autoinjectors. Furthermore, favorable regulatory and reimbursement policies in North America and Europe increase the adoption of autoinjectors in the region.

Autoinjectors Market - Global Forecast To 2030

To know about the assumptions considered for the study, Request for Free Sample Report

Autoinjector Finished Formulations Market - Global Forecast To 2030

Autoinjectors Market Opportunities

Global Autoinjectors Market Dynamics

Driver: Increasing regulatory approvals for autoinjectors

Favorable regulatory scenarios and frequent authorizations for novel autoinjector devices are significant factors that uplift market growth. The US FDA has approved biologics such as Humira (adalimumab) to treat rheumatoid arthritis, which, in turn, further drives the global demand for autoinjectors. Introducing new categories, such as GLP-1, has also resulted in fewer injections and more compliance with treatment programs. Furthermore, using technologically advanced autoinjectors has improved disease management by allowing dosage tracking and data exchange. For example, in 2024, LEO Pharma got US FDA clearance for Adbry (tralokinumab-ldrm), which is licensed for atopic dermatitis in adults and children (12 years and older).

Restraint: Focus on needle-free drug delivery systems and prevalence of needle phobia

Traditional injectables with vials and syringes are invasive and painful modes of drug delivery, owing to which patients and care providers have focused on alternative routes such as oral, topical, and nasal routes. The oral route is preferred because it is convenient, cost-effective, safe, and acceptable. The market is likely to experience a negative impact on future growth due to the introduction of needle-free drug delivery devices, such as jet injectors. For example, Crossject offers ZENEO, a needle-free autoinjector, and PharmaJet provides the Stratis Needle-free Injection System.

Furthermore, needleless devices provide the benefit of alleviating needle phobia, a significant obstacle to the widespread acceptance of injectable medication. A lack of adherence among both children and adults is mainly due to the discomfort associated with frequent injections and the ongoing need for therapy. Patients with diabetes, rheumatoid arthritis, growth hormone deficiency, and other conditions that necessitate weekly injection therapy through autoinjectors are hindered by needle anxiety, which in turn hampers market expansion.

Opportunity: Launch of technologically advanced autoinjectors

Investment in the launch of technologically advanced autoinjectors with smart connectivity has propelled the market growth. The launch of advanced autoinjectors with integration of Bluetooth data connectivity with smartphones further creates lucrative growth opportunities in the coming years. For instance, the currently available RebiSmart autoinjector used for multiple sclerosis is designed with built-in Bluetooth connectivity, which allows patients to track their injection history using a smartphone app.

The adoption of advanced polymers and other materials in autoinjectors has also increased the tenure and performance of these devices, allowing for constant operation in various conditions. Technological improvements have altered the autoinjector market by improving the devices' intelligence, comfort, and use. These advancements help patients comply with therapy, reduce mistake risks, and ultimately improve health outcomes. All the variables listed above are projected to promote market expansion in the future.

Challenge: Development of autoinjectors for multiple drug viscosities

Autoinjectors help deliver an accurate volume of drugs/medications at a precise injection speed, and these parameters can be hampered by the viscosity of the drug to be given in the form of an autoinjector. Viscosity refers to the resistance or thickness of a liquid flow, which can be affected by factors such as biologics, chemical properties, and the strength of the active ingredient.

Medications with diverse viscosities require springs with different physical features, such as length, composition, and thickness, to create a spring rate that provides enough power to push higher-viscosity drugs and biologics through the syringe to the needle. The development of an autoinjector that can consistently deliver drugs with different viscosities can be challenging since the device needs to hold a range of injection speeds and volumes while maintaining accuracy and safety.

Global Autoinjectors Ecosystem Analysis

The autoinjectors market operates within a complex ecosystem that includes a wide array of stakeholders, each playing a crucial role in developing and adopting autoinjectors. This ecosystem encompasses autoinjector device and finished formulation manufacturers, biopharmaceutical companies, and regulatory bodies.

The disposable segment accounted for the largest market share in 2023.

Autoinjectors are categorized as reusable and disposable autoinjectors, based on their usage. In 2023, the disposable segment accounted for the most significant autoinjector devices and finished formulations market share. This segment’s large share can primarily be attributed to technological advancements and the inclusion of various features such as Bluetooth connectivity and dosage count, among others. Furthermore, the reusable autoinjectors segment has gained significant demand owing to cost-effectiveness over time, customized solutions in reusable autoinjectors, and multi-dose capability. These factors are likely to have a positive impact on market growth.

The subcutaneous route of administration segment dominated the autoinjectors market in 2023.

Based on the route of administration, the autoinjectors market is further categorized into subcutaneous and intramuscular routes of administration. In 2023, the subcutaneous route of administration dominated the autoinjectors market. The presence of various drugs for the scrutinous rounds of administration and a slower absorption of medication into the bloodstream through the subcutaneous route of administration is expected to drive segment growth. The intramuscular route of the administration segment is also likely to grow at a significant CAGR during the forecast period.

North America was the largest regional market for the Autoinjectors market in 2023.

Based on the region, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global autoinjector devices and finished formulations market in 2023 and will likely dominate throughout the forecast period. The rising adoption of self-administration among patient populations and cost-effectiveness boost the market growth. Also, the high prevalence of chronic diseases, favorable regulatory environment, and adequate reimbursement policies spur market growth. The Asia Pacific region is projected to grow at the highest CAGR during the study period. Factors such as a favorable regulatory environment, a shift towards home-based care in the Asia Pacific region, and a rise in funding for developing novel devices are likely to uplift the market growth in the Asia Pacific region.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the autoinjectors market include SHL Medical AG (Switzerland), Ypsomed AG (Switzerland), Becton, Dickinson and Company (BD) (US), Recipharm AB (Sweden), West Pharmaceutical Services, Inc.(US), Phillips-Medisize (US), Halozyme, Inc. (US), Owen Mumford Ltd. (UK), Gerresheimer AG (Germany), Haselmeier (Germany), Oval Medical Technologies Ltd. (UK), Kaleo, Inc. (US), Solteam Incorporation Co., Ltd. (China), Elcam Drug Delivery Devices (Israel), Crossject (France), Jabil, Inc. (US), Congruence Medical Solutions LLC (US), Midas Pharma GMBH (Germany).

Some of the major market players for finished formulations covered in this chapter include Abbvie Inc. (US), Eli Lilly and Company (US), Amgen Inc. (US), Novo Nordisk A/S (Denmark), Jonhson & Jonhson Services Inc. (US), Sanofi (France), GSK plc (UK).

Scope of the Autoinjectors Market Report

This report categorizes the autoinjectors market into the following segments:

Autoinjectors Market, by Usage

• Disposable Autoinjectors
• Reusable Autoinjectors

Autoinjectors Market, by Technology

• Manual Autoinjectors
• Automatic Autoinjectors

Autoinjectors Market, by Route of administration

• Subcutaneous
• Intramuscular

Autoinjectors Market, by Volume

• Upto 3ml
• Above 3ml

Autoinjectors Market, by Therapy Area

• Rheumatoid Arthritis
• Diabetes
• Multiple Sclerosis
• Anaphylaxis
• Obesity
• Other therapy areas

Autoinjectors Market, by End User

• Home Care Settings
• Hospitals & Clinical Settings
• Ambulatory Care Settings

Autoinjectors Market, by Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • Japan
  • India
  • China
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • RoLATAM (RoLATAM)
• Middle East & Africa
  • GCC Countries
  • Rest of Middle East & Africa (RoMEA)

Recent Developments

• In November 2023, Zepbound (tirzepatide), a potent new therapy option developed by Eli Lilly and Company (US) for obesity or overweight with weight-related medical issues, was approved by the US FDA for chronic weight control.
• In October 2023, SHL Medical AG (Switzerland) introduced the Molly Connected Cap autoinjector, a tiny and retrofittable add-on that captures and sends patient usage data.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst